These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 294306)
1. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report. Chard RL; Krivit W; Bleyer WA; Hammond D Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group. Bleyer WA; Krivit W; Chard RL; Hammond D Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803 [TBL] [Abstract][Full Text] [Related]
3. [VP 16-213 in the treatment of acute leukemia in childhood]. Esumi N; Arakawa S; Imashuku S Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730 [TBL] [Abstract][Full Text] [Related]
4. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia. Van Echo DA; Wiernik PH; Aisner J Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027 [TBL] [Abstract][Full Text] [Related]
5. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Early AP; Preisler HD; Slocum H; Rustum YM Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors]. Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137 [TBL] [Abstract][Full Text] [Related]
7. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies]. Kimura K; Yamada K; Yoshida T Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373 [TBL] [Abstract][Full Text] [Related]
8. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine. Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431 [TBL] [Abstract][Full Text] [Related]
9. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia]. Esumi N; Todo S; Arakawa S; Imashuku S Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923 [TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of diaziquone in childhood cancer. Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of VP-16-213 in malignant lymphoma and melanoma. Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164 [TBL] [Abstract][Full Text] [Related]
13. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer. Tan CT; Hancock CH; Mondora A; Hoffman NW Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381 [TBL] [Abstract][Full Text] [Related]
15. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia]. Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288 [No Abstract] [Full Text] [Related]
16. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Finklestein JZ; Higgins G; Krivit W; Hammond D Cancer Treat Rep; 1979 Aug; 63(8):1331-3. PubMed ID: 89907 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of vindesine in patients with acute leukemia. Sklaroff RB; Arlin Z; Young CW Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307 [TBL] [Abstract][Full Text] [Related]
18. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders]. Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424 [TBL] [Abstract][Full Text] [Related]
19. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323 [TBL] [Abstract][Full Text] [Related]
20. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Schiffer CA; DeBellis R; Kasdorf H; Wiernik PH Cancer Treat Rep; 1982 Feb; 66(2):267-71. PubMed ID: 6173123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]